Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityNo recent work listed

Qiqing Sun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0003-8564-0962; OpenAlex author ID A5063713824. Sources: OpenAlex.

Their work

Papers
13
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2018: 2 papers · 2019: 7 papers · 2020: 4 papers

Papers 13

  1. Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis. Co-author DOI 10.1038/s41388-020-01452-3↗
  2. Pin1 promotes pancreatic cancer progression and metastasis by activation of NF-κB-IL-18 feedback loop. Co-author DOI 10.1111/cpr.12816↗
  3. Comments: The Prognostic Index Independently Predicts Survival in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Resection. Co-author DOI 10.1245/s10434-020-08369-x↗
  4. Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells. Co-author PMID 32368394↗
  5. UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.03.024↗
  6. ABO Blood Group and the Risk of Pancreatic Neoplasms in Chinese Han Population: A Study at Shanghai Pancreatic Cancer Institute. Co-author DOI 10.1097/mpa.0000000000001408↗
  7. Homeodomain-interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer. Co-author DOI 10.1111/cpr.12603↗
  8. Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12935-019-0767-4↗
  9. Prognostic and diagnostic significance of galectins in pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.1186/s12935-019-1025-5↗
  10. PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis. Co-author DOI 10.1186/s12964-019-0344-4↗
  11. FGFBP1, a downstream target of the FBW7/c-Myc axis, promotes cell proliferation and migration in pancreatic cancer. Co-author PMID 31911852↗
  12. dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer. Co-author DOI 10.1111/cpr.12456↗
  13. The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer. Co-author DOI 10.7150/thno.26546↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yi Qin · 12 shared papers, 2018–2020 · strength 1.08
  2. Xianjun Yu · 11 shared papers, 2018–2020 · strength 0.98
  3. Shunrong Ji · 10 shared papers, 2018–2020 · strength 0.89
  4. Qiangsheng Hu · 10 shared papers, 2018–2020 · strength 0.89
  5. Wenyan Xu · 10 shared papers, 2018–2020 · strength 0.89
  6. Wensheng Liu · 10 shared papers, 2018–2020 · strength 0.89
  7. Xiaowu Xu · 9 shared papers, 2019–2020 · strength 0.84
  8. Zheng Zhang · 9 shared papers, 2018–2020 · strength 0.80
  9. Mengqi Liu · 5 shared papers, 2019–2020 · strength 0.46
  10. Ye Zeng · 4 shared papers, 2019–2020 · strength 0.40
  11. Quanxing Ni · 4 shared papers, 2018–2019 · strength 0.33
  12. Jin Xu · 4 shared papers, 2018–2019 · strength 0.33
  13. Yiyin Zhang · 2 shared papers, 2019–2020 · strength 0.30
  14. Qifeng Zhuo · 3 shared papers, 2020 · strength 0.29
  15. Xiaowu Xu · 2 shared papers, 2019–2020 · strength 0.28
  16. Bo Zhang · 3 shared papers, 2018–2019 · strength 0.24
  17. Mengqi Liu · 2 shared papers, 2019 · strength 0.20
  18. Jinfeng Xiang · 2 shared papers, 2018–2019 · strength 0.16
  19. Xianjun Yu · 1 shared paper, 2020 · strength 0.10
  20. Wenyan Xu · 1 shared paper, 2019 · strength 0.09
  21. Ye Zeng · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.